Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

N/A

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05656131Phase 2Suspended

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Role: lead

NCT05978648Phase 2Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Role: lead

NCT05390476Phase 2Unknown

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Role: lead

NCT05411380Phase 2Unknown

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Role: lead

NCT02448576Not ApplicableUnknown

PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy

Role: lead

NCT02761460Phase 3Unknown

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

Role: lead

All 6 trials loaded